The competitive landscape of drug fabrication is currently defined by massive consolidation and the pursuit of technological superiority. Large pharmaceutical entities are acquiring smaller, tech-focused manufacturing firms to gain access to proprietary delivery systems, such as lipid nanoparticles for mRNA vaccines. This era of "super-manufacturing" requires a blend of traditional chemical...